ARTICLE | Company News
ImmunoPharmaceutics Inc. other research news
September 13, 1993 7:00 AM UTC
The company received a $50,000 Phase I SBIR from the National Institutes of Mental Health to use its bioactive compound mapping technology to develop an oral formulation of galanin antagonists to trea...